Kokudo Takashi, Kokudo Norihiro
National Center for Global Health and Medicine, Tokyo 162-8655, Japan.
Cancers (Basel). 2025 Feb 3;17(3):507. doi: 10.3390/cancers17030507.
Since their introduction in the 1990s, the Milan criteria have been the gold standard of indication for liver transplantation (LT) in patients with hepatocellular carcinoma (HCC). Nevertheless, several institutions have reported wider indication criteria for LT with comparable survival outcomes. This paper summarizes the recent indications for LT for HCC through a literature review. There are several criteria expanding the Milan criteria, which can be subdivided into the "based on tumor number and size only", "based on tumor number and size plus tumor markers", and "based on tumor differentiation" groups, with the outcomes being comparable to those of patients included within the Milan criteria. Besides the tumor size and number, which are included in the Milan criteria, recent criteria included biomarkers and tumor differentiation. Several retrospective studies have reported microvascular invasion (MVI) as a significant risk factor for postoperative recurrence, highlighting the importance of preoperatively predicting MVI. Several studies attempted to identify preoperative predictive factors for MVI using tumor markers or preoperative imaging findings. Patients with HCC who are LT candidates are often treated while on the waiting list to prevent the progression of HCC or to reduce the measurable disease burden of HCC. The expanding repertoire of chemotherapeutic regiments suitable for patients with HCC should be further investigated. : There are several criteria expanding Milan criteria, with the outcomes being comparable to those of patients included within the Milan criteria.
自20世纪90年代引入以来,米兰标准一直是肝细胞癌(HCC)患者肝移植(LT)的金标准适应证。然而,一些机构报告了更宽松的LT适应证标准,且生存结果相当。本文通过文献综述总结了近期HCC的LT适应证。有几个标准扩展了米兰标准,可分为“仅基于肿瘤数量和大小”、“基于肿瘤数量和大小加肿瘤标志物”以及“基于肿瘤分化”组,其结果与米兰标准所涵盖患者的结果相当。除了米兰标准中包含的肿瘤大小和数量外,近期标准还纳入了生物标志物和肿瘤分化。几项回顾性研究报告称微血管侵犯(MVI)是术后复发的重要危险因素,凸显了术前预测MVI的重要性。几项研究试图使用肿瘤标志物或术前影像学检查结果来识别MVI的术前预测因素。作为LT候选者的HCC患者在等待名单上时通常会接受治疗,以防止HCC进展或减轻可测量的HCC疾病负担。适合HCC患者的化疗方案不断增加,对此应进一步研究。:有几个标准扩展了米兰标准,其结果与米兰标准所涵盖患者的结果相当。